-
The net profit of pharmaceutical stocks soared from 50 million to 16 billion, and only 3 companies lost money
Time of Update: 2022-10-25
Jiuan Medical soared 300 times to become the "growth king", the net profit soared from 50 million yuan to 16 billion yuan, the CXO leading performance soared, and chain giants such as Laobai, Da Shenlin and Yifeng steadily climbed.
-
of 3 companies including Changchun Hi-Tech and Hengrui increased by over 80% year-on-year
Time of Update: 2022-05-09
Judging from the three pharmaceutical companies with a gross profit margin of over 80%, Changchun Hi-Tech will achieve a net profit of 610 million yuan in 2021, a year-on-year decrease of 22.
-
11 medical device companies disclosed their annual reports, and 3 companies’ net profit growth rate exceeded 100%
Time of Update: 2022-04-15
Leadman's 2021 annual report shows that during the reporting period, the company achieved operating income of 564 million yuan, a year-on-year increase of 19.
The company plans to distribute cash dividends of 22 yuan (tax included) for every 10 shares to all shareholders .
-
Another drug consistency evaluation has been evaluated by 3 companies!
Time of Update: 2019-11-26
According to pharmaceutical intelligence news, on November 26, Hyundai pharmaceutical released an enterprise announcement that indapamide tablets, a wholly-owned subsidiary of Shanghai Hyundai Pharmac
-
There are 3 companies that have evaluated the consistency of another variety
Time of Update: 2019-05-13
Recently, the official website of Chongqing kangkeri Co., Ltd announced that its company has received the approval document for supplementary drug application (approval No.: 2019b02914) of glimepiride
-
There are 3 companies that have evaluated the consistency of another variety
Time of Update: 2019-05-13
Recently, the official website of Chongqing kangkeri Co., Ltd announced that its company has received the approval document for supplementary drug application (approval No.: 2019b02914) of glimepiride
-
2. The drug was removed from the Internet, because it failed to pass the consistency evaluation and had been evaluated by 3 companies
Time of Update: 2019-03-20
On March 20, Jiangxi Medical purchasing service center issued the notice of Jiangxi Province on adjusting the purchasing qualification of some products in 2019 Among them, 2 drugs failed to pass the c
-
Guangdong pharmaceutical companies urgently resumed production of ibuprofen tablets with a daily production capacity of 3 million tablets
Time of Update: 2023-02-03
js?cdnversion='+~(-new Date()/36e5)];On the 29th, in the production workshop of Baiyunshan Pharmaceutical General Factory of Guangzhou Pharmaceutical Group located in Baiyun District, Guangzhou, the roar of machines echoed in my ears.
-
2022 inventory: A-share pharmaceutical companies rose TOP10, ibuprofen took the top spot, and 3 rose by more than 100%
Time of Update: 2023-02-03
It involves antipyretic drugs, antigen tests, new crown specific drugs, and antiviral drugsAccording to the data of Flush Finance, the top ten pharmaceutical companies (excluding medical devices, pharmaceutical businesses, and medical service companies) in A-shares in 2022 are:Xinhua Pharmaceutical, Zhongsheng Pharmaceutical, Shanghai Yizhong, Weixinkang, Rongchang Biotechnology, Haichen Pharmaceutical, Enhua Pharmaceutical, Yiling Pharmaceutical, Shuangcheng Pharmaceutical, Huatedyne.
-
The mergers and acquisitions of listed companies are hot, and there are 3 pharmaceutical companies in 1 day!
Time of Update: 2023-01-06
On the same day, Tailong Pharmaceutical issued an announcement on the participation of the company's wholly-owned subsidiary in the establishment of pharmaceutical industry funds and related party transactions, and the company's wholly-owned subsidiary Tailong Health intends to invest 10 million yuan to establish a new wholly-owned subsidiary Hangzhou Tailong Jintang Enterprise Management Co.
-
The mergers and acquisitions of listed companies are hot, and there are 3 pharmaceutical companies in 1 day!
Time of Update: 2023-01-06
On the same day, Tailong Pharmaceutical issued an announcement on the participation of the company's wholly-owned subsidiary in the establishment of pharmaceutical industry funds and related party transactions, and the company's wholly-owned subsidiary Tailong Health intends to invest 10 million yuan to establish a new wholly-owned subsidiary Hangzhou Tailong Jintang Enterprise Management Co.
-
This pharmaceutical company has another drug review! Since the second half of the year, a total of 3 varieties have been evaluated
Time of Update: 2023-01-05
According to the announcement, isoniazid tablets (specifications: 300mg, 100mg) of Mingxing Pharmaceutical, a wholly-owned subsidiary of the company, have passed the consistency evaluation of the quality and efficacy of generic drugs.
-
3 instrument companies listed in a group The Beijing Stock Exchange accelerated its expansion to attract specialized and special new enterprises
Time of Update: 2023-01-04
Original: 3 instrument companies listed in a group The Beijing Stock Exchange accelerated its expansion to attract specialized and special new enterprises 【Chemical Machinery and Equipment Network Industry News】On October 18, Zhongke Meiling (835892) was officially listed on the Beijing Stock Exchange, which lasted only 111 days from the acceptance of the IPO application to the issuance and listing, refreshing the speed of listing review and issuance on the Beijing Stock Exchange.
-
The world's top 20 fossil fuel companies account for 1/3 of global carbon emissions
Time of Update: 2023-01-02
fossil fuel The new study found that the top 20 companies on the list contribute 35% of all energy-related carbon dioxide and methane emissions globally, adding a total of 480 billion tonnes of CO2 equivalent since 1965.
-
This 5-day, 3-board pharmaceutical stock was fined more than the company's net profit in the first three quarters because of monopoly
Time of Update: 2022-12-30
News on December 13, Northeast Pharmaceutical announced that the company recently received the "Administrative Penalty Notice" issued by the Liaoning Provincial Administration for Market Regulation, because the company violated the anti-monopoly law by selling L-carnitine APIs at unfairly high prices between November 2018 and June 2019, and the company was fined a total of 133 million yuan.
